Descriptive only
Fibrosis improvement without worsening of steatohepatitis
Metabolic dysfunction associated steatotic liver disease or steatohepatitis
weeks 48 to 104 (target week 72)Hypothetical (as if everyone stayed on treatment)Each dose separatelyOdds ratio
1
Randomized trials
4
Treatments
155
Participants
78
Events
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Fibrosis stage (NASH CRN stage) effect modifier, prognostic factor; 1 of 1 |
|---|---|
| SYNERGY-NASH S000031 | F2 36%, F3 64% |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- NoteData handling, input conversions: count_from_percent 4
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SYNERGY-NASH | 52 | other | Absence of NASH with no worsening of fibrosis;Fibrosis decrease of 1 stage or more with no worsening of NASH | not stated | not stated | not_stated | hypothetical | not stated | double_blind | industry | 2019 | age 18 to 80, BMI 27 to 50, biopsy MASH with NAS 4 or more and fibrosis F2 to F3, HbA1c up to 9.5 percent |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the odds ratio on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| SYNERGY-NASH | A1 | TIRZ_SC_5MG_QW | 52 | arm, responders | 23 / 39 | count_from_percent | registry:outcomes | ||
| SYNERGY-NASH | A2 | TIRZ_SC_10MG_QW | 52 | arm, responders | 22 / 41 | count_from_percent | registry:outcomes | ||
| SYNERGY-NASH | A3 | TIRZ_SC_15MG_QW | 52 | arm, responders | 22 / 40 | count_from_percent | registry:outcomes | ||
| SYNERGY-NASH | A4 | PLACEBO | 52 | arm, responders | 11 / 35 | count_from_percent | registry:outcomes |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.